FDA Determines Regulatory Review Period for HYMOVIS Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of HYMOVIS, a medical device, as required by law, following a submission to the U.S. Patent and Trademark Office (USPTO).